Abstract
The implantable cardioverter defibrillator (ICD) is a life-saving therapy in patients at risk for sudden cardiac death, but the traditional transvenous lead system comes with risks and complications related to intravascular and intracardiac placement of the leads. The subcutaneous ICD (SICD) is an effective alternative option in select patients at risk for intravascular device complications. The goal of this chapter is to discuss indications, implantation techniques and testing of the S-ICD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, Knops RE, Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-Year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65:1605–15.
Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder IC, Wilde AA, van Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36–44.
McLeod CJ, Boersma L, Okamura H, Friedman PA. The subcutaneous implantable cardioverter defibrillator: state-of-the-art review. Eur Heart J. 2017;38:247–57.
Swerdlow CD, Asirvatham SJ, Ellenbogen KA, Friedman PA. Troubleshooting implantable cardioverter-defibrillator sensing problems II. Circ Arrhythm Electrophysiol. 2015;8:212–20.
Rowley CP, Gold MR. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2012;5:587–93.
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2018;15:e190–252.
de Bie MK, Thijssen J, van Rees JB, Putter H, van der Velde ET, Schalij MJ, van Erven L. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart. 2013;99:1018–23.
Noheria A, Cha YM, Asirvatham SJ, Friedman PA. Shoulder joint dislocation as an unusual complication of defibrillation threshold testing following subcutaneous implantable cardioverter-defibrillator implantation. Indian Pacing Electrophysiol J. 2014;14:297–300.
Chue CD, Kwok CS, Wong CW, Patwala A, Barker D, Zaidi A, Mamas MA, Cunnington C, Ahmed FZ. Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: a systematic review. Heart. 2017;103:1315–22.
Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P, Duffy E, Husby M, Stein K, Lambiase PD, Group EI. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the effortless study. J Am Coll Cardiol. 2017;70:830–41.
Gold MR, Aasbo JD, El-Chami MF, Niebauer M, Herre J, Prutkin JM, Knight BP, Kutalek S, Hsu K, Weiss R, Bass E, Husby M, Stivland TM, Burke MC. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14:1456–63.
Quast ABE, Baalman SWE, Brouwer TF, Smeding L, Wilde AAM, Burke MC, Knops RE. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: the PRAETORIAN score. Heart Rhythm. 2019;16:403–10.
Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, Delnoy PP, van Dessel PF, Driessen AH, de Groot JR, Herrman JP, Jordaens LJ, Kooiman KM, Maass AH, Meine M, Mizusawa Y, Molhoek SG, van Opstal J, Tijssen JG, Wilde AA. Rationale and design of the PRAETORIAN trial: a prospective, randomized comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy. Am Heart J. 2012;163:753–60 e2.
Mondesert B, Bashir J, Philippon F, Dubuc M, Amit G, Exner D, Joza J, Birnie DH, Lane C, Tsang B, Korley V, Spears D, Ling A, Djuric A, Crystal E, Hruczkowski T, Roux JF, Carroll S, Essebag V, Krahn AD, Healey JS. Rationale and design of the randomized prospective ATLAS study: avoid transvenous leads in appropriate subjects. Am Heart J. 2019;207:1–9.
Gold MR, Knops R, Burke MC, Lambiase PD, Russo AM, Bongiorni MG, Deharo JC, Aasbo J, El Chami MF, Husby M, Carter N, Boersma L. The Design of the understanding outcomes with the S-ICD in primary prevention patients with low EF study (UNTOUCHED). Pacing Clin Electrophysiol. 2017;40:1–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bibby, P.S., Barake, W., Mulpuru, S.K. (2021). Use of the Subcutaneous Implantable Cardioverter Defibrillator in Patients with Heart Failure. In: Birgersdotter-Green, U., Adler, E. (eds) Case-Based Device Therapy for Heart Failure. Springer, Cham. https://doi.org/10.1007/978-3-030-70038-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-70038-6_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70037-9
Online ISBN: 978-3-030-70038-6
eBook Packages: MedicineMedicine (R0)